Omecamtiv mecarbil, a cardiac myosin activator, increases ca2+ sensitivity in myofilaments with a dilated cardiomyopathy mutant tropomyosin E54K

Journal of Cardiovascular Pharmacology

Volumn 66, Issue 4, 2015, Pages 347-353

  Utter, Megan S ^a   Ryba, David M ^a   Li, Betty H ^a   Wolska, Beata M ^a   Solaro, R John ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

ATPase activity; Ca sensitization; sarcomere

Indexed keywords

ACTIN; ADENOSINE TRIPHOSPHATASE; CALCIUM ION; CARDIAC MYOSIN; MYOSIN; MYOSIN BINDING PROTEIN C; OMECAMTIV MECARBIL; TROPOMYOSIN; TROPONIN I; TROPONIN T; CALCIUM; TPM1 PROTEIN, MOUSE; UREA;

ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; CALCIUM SENSITIVITY; CONCENTRATION RESPONSE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DESENSITIZATION; EC50; FEMALE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; INOTROPISM; LEFT VENTRICULAR PAPILLARY MUSCLE; MALE; MOUSE; MUSCLE FIBRIL; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; SARCOMERE; ANALOGS AND DERIVATIVES; ANIMAL; CARDIOMYOPATHY, DILATED; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; TRANSGENIC MOUSE;

ANIMALS; CALCIUM; CARDIAC MYOSINS; CARDIOMYOPATHY, DILATED; DISEASE MODELS, ANIMAL; MICE, TRANSGENIC; MUTATION; MYOFIBRILS; TROPOMYOSIN; UREA;

EID: 84943635540     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000286     Document Type: Article

References (33)

1. Towbin JA. Inherited cardiomyopathies. Circ J. 2014;78:2347-2356.
2. Olson TM, Kishimoto NY, Whitby FG, et al. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J Mol Cell Cardiol. 2001;33:723-732.
3. McLachlan AD, Stewart M. The 14-fold periodicity in alpha-tropomyosin and the interaction with actin. J Mol Biol. 1976;103:271-298.
4. Rajan S, Ahmed RP, Jagatheesan G, et al. Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity. Circ Res. 2007;101:205-214.
5. Chang AN, Harada K, Ackerman MJ, et al. Functional consequences of hypertrophic and dilated cardiomyopathy-causing mutations in alphatropomyosin. J Biol Chem. 2005;280:34343-34349.
6. Mirza M, Marston S, Willott R, et al. Dilated cardiomyopathy mutations in three thin filament regulatory proteins result in a common functional phenotype. J Biol Chem. 2005;280:28498-28506.
7. Mirza M, Robinson P, Kremneva E, et al. The effect of mutations in alpha-tropomyosin (E40K and E54K) that cause familial dilated cardiomyopathy on the regulatory mechanism of cardiac muscle thin filaments. J Biol Chem. 2007;282:13487-13497.
8. McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med. 2010;362:228-238.
9. Kass DA, Solaro RJ, Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation. 2006;113:305-315.
10. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998;339:1810-1816.
11. Petersen JW, Felker GM. Inotropes in the management of acute heart failure. Crit Care Med. 2008;36(1 suppl):S106-S111.
12. Teerlink JR. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev. 2009;14:289-298.
13. Malik FI, Morgan BP. Cardiac myosin activation part 1: from concept to clinic. J Mol Cell Cardiol. 2011;51:454-461.
14. Solaro RJ. CK-1827452, a sarcomere-directed cardiac myosin activator for acute and chronic heart disease. IDrugs. 2009;12:243-251.
15. Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331:1439-1443.
16. Komamura K, Shannon RP, Pasipoularides A, et al. Alterations in left ventricular diastolic function in conscious dogs with pacing-induced heart failure. J Clin Invest. 1992;89:1825-1838.
17. Shen YT, Malik FI, Zhao X, et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail. 2010;3:522-527.
18. Fish R, Danneman PJ, Brown M, et al. Anesthesia and Analgesia in Laboratory Animals. Amsterdam, The Netherlands: Elsevier Science; 2011.
19. Solaro RJ, Pang DC, Briggs FN. The purification of cardiac myofibrils with Triton X-100. Biochim Biophys Acta. 1971;245: 259-262.
20. Layland J, Cave AC, Warren C, et al, Protection against endotoxemiainduced contractile dysfunction in mice with cardiac-specific expression of slow skeletal troponin I. FASEB J. 2005;19:1137-1139.
21. Kobayashi T, Solaro RJ. Increased Ca2+ affinity of cardiac thin filaments reconstituted with cardiomyopathy-related mutant cardiac troponin I. J Biol Chem. 2006;281:13471-13477.
22. Kodama T, Fukui K, Kometani K. The initial phosphate burst in ATP hydrolysis by myosin and subfragment-1 as studied by a modified malachite green method for determination of inorganic phosphate. J Biochem. 1986;99:1465-1472.
23. Wolska BM, Keller RS, Evans CC, et al. Correlation between myofilament response to Ca2+ and altered dynamics of contraction and relaxation in transgenic cardiac cells that express beta-tropomyosin. Circ Res. 1999;84:745-751.
24. Takeda S, Kobayashi T, Taniguchi H, et al. Structural and functional domains of the troponin complex revealed by limited digestion. Eur J Biochem. 1997;246:611-617.
25. Yates LD, Greaser ML. Quantitative determination of myosin and actin in rabbit skeletal muscle. J Mol Biol. 1983;168:123-141.
26. Fritz JD, Swartz DR, Greaser ML. Factors affecting polyacrylamide gel electrophoresis and electroblotting of high-molecular-weight myofibrillar proteins. Anal Biochem. 1989;180:205-210.
27. Nonaka M, Morimoto S, Murayama T, et al. Stage-dependent benefits and risks of pimobendan in genetic dilated cardiomyopathy mice with progressive heart failure. Br J Pharmacol. 2015;172:2369-2382.
28. Du CK, Zhan DY, Morimoto S. In vivo effects of propyl gallate, a novel Ca(2+) sensitizer, in a mouse model of dilated cardiomyopathy caused by cardiac troponin T mutation. Life Sci. 2014;109:15-19.
29. Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, Mebazaa A. Levosimendan: from basic science to clinical practice. Heart Fail Rev. 2009;14: 265-275.
30. Edes I, Kiss E, Kitada Y, et al. Effects of Levosimendan, a cardiotonic agent targeted to troponin-c, on cardiac-function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic-reticulum in guinea-pig heart. Circ Res. 1995;77:107-113.
31. Sweeney HL, Houdusse A. Structural and functional insights into the myosin motor mechanism. Annu Rev Biophys. 2010;39:539-557.
32. Holmes KC, Angert I, Kull FJ, et al. Electron cryo-microscopy shows how strong binding of myosin to actin releases nucleotide. Nature. 2003; 425:423-427.
33. Arteaga GM, Kobayashi T, Solaro RJ. Molecular actions of drugs that sensitize cardiac myofilaments to Ca2+. Ann Med. 2002;34:248-258.